---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-250816"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-10-04T23:59:59+00:00"
generated_at: "2026-06-10T04:50:34.058594+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Vaxcyte and Sutro finalize Form Definitive Agreement; amend license terms

## Summary
- On Sep 28, 2023, Vaxcyte and Sutro mutually agreed on the Form Definitive Agreement to become effective if Vaxcyte exercises the option to source extract.
- Concurrently, the companies entered the 2023 Amendment to the Sutro License Agreement, modifying royalty reductions, IP prosecution, and royalty payment reporting.
- The previously agreed $5.0M cash payment to Sutro remains due within five business days after mutual agreement on the Form Definitive Agreement.

## SEC filing metadata
- accession: 0001193125-23-250816
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312523250816/0001193125-23-250816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312523250816/d548055d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-250816
- JSON: https://secwatch.observer/filing/0001193125-23-250816.json
- Plain text: https://secwatch.observer/filing/0001193125-23-250816.txt

## Key facts
- Material Agreements
  Vaxcyte, Inc. amended 2023 Amendment with Sutro Biopharma, Inc. (effective 2023-09-28).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Sutro Biopharma, Inc.
  - Effective: 2023-09-28
  source text: Concurrent with the Companies’ mutual agreement upon the Form Definitive Agreement on September 28, 2023, the Companies entered into the 2023 Amendment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000119312523250816/0001193125-23-250816-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.